Chapter 27: Antituberculars, Antifungals, and Antivirals

Chapter 27: Antituberculars, Antifungals, and Antivirals

 

Complete Chapter Questions With Answers

 

Sample Questions Are Posted Below

 

MULTIPLE CHOICE

 

1. Which person should be treated with prophylactic antitubercular medication?

a.	A child who attends the same school with a child who has tuberculosis
b.	A nurse who is working in a hospital
c.	An individual who is HIV-positive with a negative TB skin test
d.	A patient who has close contact with someone who has tuberculosis

 

 

ANS:   D

Personal contact with a person having a diagnosis of tuberculosis is required to indicate prophylactic treatment with antitubercular therapy. Attending the same school does not necessarily mean close contact occurs. Health care professionals do not need prophylactic treatment. HIV-positive individuals with negative TB skin tests do not need prophylaxis.

 

DIF:    Cognitive Level: Applying (Application)                              REF:    p. 375

TOP:    Nursing Process: Assessment

MSC:   NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies

 

2. A patient who has chronic liver disease reports contact with a person who has tuberculosis (TB). The nurse will counsel this patient to contact the provider to discuss

a.	a chest x-ray.
b.	a TB skin test.
c.	liver function tests (LFTs).
d.	prophylactic antitubercular drugs.

 

 

ANS:   B

Patients who have exposure to TB should have a TB skin test. A chest x-ray is performed if the skin test is positive. LFTs do not need to be done simply because of TB exposure. This patient is not a candidate for antitubercular drug prophylaxis.

 

DIF:    Cognitive Level: Understanding (Comprehension)               REF:    p. 375

TOP:    Nursing Process: Nursing Intervention

MSC:   NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies

 

3. A patient who has tuberculosis asks the nurse why three drugs are used to treat this disease. The nurse will explain that multidrug therapy is used to reduce the likelihood of

a.	disease relapse.
b.	drug hypersensitivity reactions.
c.	drug resistance.
d.	drug adverse effects.

 

 

ANS:   C

Without multidrug therapy, patients easily develop resistance to antitubercular drugs. Using more than one antitubercular drug does not prevent relapse, hypersensitivity reactions, or adverse effects.

 

DIF:    Cognitive Level: Understanding (Comprehension)               REF:    p. 377

TOP:    Nursing Process: Nursing Intervention: Patient Teaching

MSC:   NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies

 

4. A patient is being treated with isoniazid (INH), rifampin, and pyrazinamide in phase I of treatment for tuberculosis. The organism develops resistance to isoniazid. Which drug will the nurse anticipate the provider will order to replace the isoniazid?

a.	Ciprofloxacin (Cipro)
b.	Ethambutol (Myambutol)
c.	Kanamycin
d.	Streptomycin sulfate

 

 

ANS:   B

If there is bacterial resistance to isoniazid, the first phase may be changed to ethambutol, rifampin, and pyrazinamide. Ciprofloxacin, kanamycin, and streptomycin are not generally first-line antitubercular drugs.

 

DIF:    Cognitive Level: Applying (Application)                              REF:    p. 377

TOP:    Nursing Process: Nursing Intervention

MSC:   NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies

 

5. The nurse is caring for a patient who is diagnosed with tuberculosis. The patient tells the nurse that the provider plans to order a prophylactic antitubercular drug for family members and asks which drug will be ordered. The nurse will expect the provider to order which drug?

a.	Isoniazid (INH)
b.	Pyrazinamide
c.	Rifampin (Rifadin)
d.	Streptomycin

 

 

ANS:   A

INH is the drug of choice for prophylactic treatment of patients who have had close contact with a patient who has tuberculosis.

 

DIF:    Cognitive Level: Understanding (Comprehension)               REF:    p. 377

TOP:    Nursing Process: Planning

MSC:   NCLEX: Physiological Integrity: Pharmacological and Parenteral Therapies